← Oncology Approval Tracker

FDA DECISION ·

Alecensa

alectinib · Genentech

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adjuvant treatment after resection for patients with ALK-positive non-small cell lung cancer, as shown by an FDA-approved test, with tumors at least 4 cm or node positive.

LAMPGEN ANALYSIS

Why it matters

The ALK inhibitor moved from advanced disease into postoperative treatment for a defined group.

What research teams should watch

Retain the surgical pathology, ALK result and nodal assessment, and track two-year oral treatment exposure and interruptions.

PRIMARY RECORDS

Sources